Paige vs Proscia (2026)
The algorithm that created the category against the platform it runs on. Paige holds the first authorization for an AI based digital pathology product, obtained through the De Novo route, which established the regulatory path everything since has used, with authorised depth in prostate cancer detection. Proscia manages and analyses whole slide data for clinical laboratories and life sciences customers, with the deeper Western installed base. A laboratory going digital needs the platform before it needs any particular detector, and then needs detectors worth running on it, so these are sequential rather than competing purchases. Neither publishes performance across the staining and scanner variation that differs between laboratories, which affects the algorithm far more than the platform.
- It produced the first authorization for an AI based digital pathology product through the De Novo route, which created the regulatory category the rest of the lane files into.
- Authorised depth in prostate cancer detection means the capability was reviewed rather than demonstrated.
- Foundation model scale work sits behind the broader ambition rather than only a fixed detector set.
- The platform manages and analyses whole slide data for clinical laboratories and life sciences customers at established scale, with the deeper Western installed base.
- Serving diagnostic work and research contracts on the same infrastructure spreads the investment across two budgets.
- For a laboratory going digital at all, the platform comes first and algorithms run on top of it.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Paige and Proscia are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Paige | Proscia |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2014 |
| Headquarters | New York, New York, United States | Philadelphia, Pennsylvania, United States |
| Website | paige.ai | proscia.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached.
The AI Health Index grades Paige A on AI Centrality and A on FDA and Regulatory Status, the second reflecting the first authorisation granted for an AI based digital pathology product, obtained through the De Novo route. Paige grades B on Autonomy and Oversight Model, B on Model and Technology Transparency, B on Clinical and Operational Evidence, B on Security Certifications and Trust Center, B on AI Governance and Bias Disclosure, B on EHR and Interoperability Depth, B on Deployment Model and Data Residency and B on AI Liability and Recourse. It grades C on AI Safety and PHI Stewardship, C on HIPAA and BAA Posture, C on Model Supply Chain Disclosure, C on Commercial Transparency and C on Setting and Specialty Coverage. The AI Health Index reading is that Paige is graded as an algorithm company holding the oldest regulatory credential in the category alongside the thinner published position on data handling, and that a pathology buyer should read the C on Setting and Specialty Coverage first, because that is the axis predicting whether a model survives contact with another laboratory's stains and scanners.
Source: AI Health Index, August 2026
The AI Health Index grades Proscia A on Autonomy and Oversight Model, A on AI Safety and PHI Stewardship, A on Security Certifications and Trust Center, A on FDA and Regulatory Status, A on Deployment Model and Data Residency and A on Model Supply Chain Disclosure, which is six top grades and the widest set held by any digital pathology vendor the AI Health Index grades. Proscia grades B on AI Centrality, B on Model and Technology Transparency, B on Clinical and Operational Evidence, B on HIPAA and BAA Posture, B on EHR and Interoperability Depth and B on Setting and Specialty Coverage, and C on AI Governance and Bias Disclosure, C on Commercial Transparency and C on AI Liability and Recourse. Against Paige the separation is on data handling rather than on regulatory standing, since both hold the top grade on FDA and Regulatory Status. Proscia grades A where Paige grades C on AI Safety and PHI Stewardship and on Model Supply Chain Disclosure, and B where Paige grades C on HIPAA and BAA Posture and on Setting and Specialty Coverage.
Source: AI Health Index, August 2026
Questions buyers ask
Paige AI vs Proscia: which should a laboratory choose?
The AI Health Index grades these two at different layers of the same purchase, which is why a laboratory often needs both rather than one. Paige is graded as an algorithm company and holds the top grade on AI Centrality and on FDA and Regulatory Status, the latter reflecting the first authorisation granted for an AI based digital pathology product.
Proscia is graded as the slide management platform that algorithms run on and holds the top grade on six axes, including Security Certifications and Trust Center, Deployment Model and Data Residency and Model Supply Chain Disclosure. A laboratory going digital buys the platform before it buys any particular detector, so sequence usually decides the order rather than a head to head comparison. Where the two do separate directly is on data handling: Proscia grades A on AI Safety and PHI Stewardship and A on Model Supply Chain Disclosure, and Paige grades C on both.
Is Paige or Proscia FDA cleared?
Both hold the top grade on FDA and Regulatory Status in the AI Health Index, and the grades cover different objects. Paige holds the first authorisation granted for an AI based digital pathology product, obtained through the De Novo route, which created the regulatory category later pathology products file into, with authorised depth in prostate cancer detection.
Proscia holds clearance for its platform for primary diagnosis and states plainly that its research edition is research use only rather than blurring the two. The AI Health Index grades regulatory standing separately from Clinical and Operational Evidence for exactly this reason: a clearance is granted for a stated indication on stated equipment, so it is not a claim about performance in general and does not extend to the next tissue or the next scanner by inheritance.
Which of Paige and Proscia publishes more about what happens to laboratory data?
Proscia, and it is the widest grade gap between the two. The AI Health Index grades Proscia A on Model Supply Chain Disclosure and A on AI Safety and PHI Stewardship, against Paige at C on both. Proscia states categorically that customer material stays inside the customer organisation unless the customer gives express permission to de identify and share it for research, and that customer data is never used to train the models the platform runs.
The AI Health Index records two residuals to obtain rather than assume: no retention or deletion position at contract end is stated, and the platform carries applications from other manufacturers, so a laboratory should confirm the commitment extends to those and not only to the platform owner's own models.
Do Paige or Proscia publish pricing?
Neither does. The AI Health Index grades both Paige and Proscia C on Commercial Transparency, the same grade the majority of its graded population carries, so a digital pathology buyer cannot establish a cost for either from public material. The AI Health Index treats choosing not to publish as a C and publishing something untrue as a D, so the grade records an absence of published material rather than a judgement about the pricing itself.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
These sit at different layers and a laboratory may well need both, since one supplies an authorised detection capability and the other supplies the slide management platform algorithms run on. Neither publishes pricing. Neither publishes subgroup or site level performance, and staining and scanner variation between laboratories remains the largest uncontrolled variable for any model either runs, which matters more for the algorithm than for the platform.